We found that treatment of tumor‐bearing mice with entinostat (a class I inhibitor, ENT) upregulates expression profiles and phenotypic features associated with improved CD8 T cell effector functions while reducing Treg‐mediated suppression within the TME and surrounding ascites. The gene discussed is CD8A; the disease is neoplasm.